FindTrial
Sign In

Comparison of topical methotrexate and topical tazarotene in psoriasis vulgaris

Comparative efficacy of topical methotrexate and topical tazarotene in psoriasis vulgaris - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059038
Enrollment
28
Registered
2023-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Topical methotrexate gel: 28 patients with bilateral lesions of psoriasis vulgaris will be asked to apply topical methotrexate on one side of the body twice daily for 8 weeks Control In

Sponsors

Government Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients of more than 18 years of age with clinical diagnosis of psoriasis vulgaris with PASI(Psoriasis area severity index) 2) Patients having bilateral skin lesions. 3) Patients who are not desirous of conception during the study period.

Exclusion criteria

Exclusion criteria: 1) Pregnant or lactating mothers. 2) Patients having any systemic illness. 3)Patients with flexural psoriasis.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of 1% topical methotrexate and 0.1% topical tazarotene in treatment of psoriasis vulgaris using PASI and mPASI scores at 2 weekly interval for 8 weeksTimepoint: 0,2,4,6,8 weeks—

Secondary

MeasureTime frame
To assess the adverse effects with both the topical therapiesTimepoint: 0,2,4,6,8 weeks—

Countries

India

Contacts

Public ContactDr Jasleen Kaur

Government Medical College and Hospital

jasleenksandhu21@gmail.com9646481249

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026